Kazia Therapeutics Liabilities 2024

Kazia Therapeutics Aktienanalyse

What does Kazia Therapeutics do?

Kazia Therapeutics Ltd is an Australian biotechnology company that specializes in the development and commercialization of novel therapeutics for the treatment of cancer and other neurological diseases. Founded in 2003 as NeuTools, the company was renamed Kazia Therapeutics in 2013, focusing on the development of cancer drugs. Kazia Therapeutics' business model is based on the use of groundbreaking sciences, such as Polycomb inhibitors, which have been identified as critical targets in cancer treatment. Kazia Therapeutics specializes in developing drugs that have higher efficacy against cancer than conventional treatments. The company has a strong pipeline of products, including Cantrixil, GDC-0084, and EVT801. Cantrixil is a drug developed for the treatment of advanced ovarian cancer. It differs from traditional chemotherapy by specifically binding to cancer cells and targeting them. In clinical trials, Cantrixil has shown promising results and is now in Phase III of clinical development. The second important product of Kazia Therapeutics is GDC-0084, which was developed as a brain tumor drug and is currently in Phase II of clinical development. GDC-0084 uses a new technology that allows the drug to be delivered directly to the brain tumor. EVT801 is a new drug being developed in collaboration with Massachusetts General Hospital. It is used for the treatment of Parkinson's disease and has the potential to be an effective alternative to existing medications. Kazia Therapeutics has partnerships with leading academic institutions and pharmaceutical companies such as Novartis, AstraZeneca, and Genentech to create synergies and bring the pipeline to market. The company is based in Sydney, Australia, and employs a small but passionate and experienced leadership team with a strong track record in the biopharmaceutical industry. Overall, Kazia Therapeutics is an innovative biotechnology company that relies on groundbreaking sciences to develop new therapies for the treatment of cancer and neurological diseases. With its promising products and partnerships, the company has the potential to improve the lives of millions of people worldwide. Kazia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Kazia Therapeutics's Liabilities

Kazia Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Kazia Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Kazia Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Kazia Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Kazia Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Kazia Therapeutics stock

What is the level of liabilities of Kazia Therapeutics this year?

Kazia Therapeutics has a debt balance of 16.03 M AUD this year.

What were the liabilities of Kazia Therapeutics compared to the previous year?

The liabilities of Kazia Therapeutics have increased by -8.97% dropped compared to the previous year.

What are the consequences of high debt for investors of Kazia Therapeutics?

High liabilities can pose a risk for investors of Kazia Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Kazia Therapeutics?

Low liabilities mean that Kazia Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Kazia Therapeutics affect the company?

An increase in liabilities of Kazia Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Kazia Therapeutics affect the company?

A decrease in the liabilities of Kazia Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Kazia Therapeutics?

Some factors that can influence the liabilities of Kazia Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Kazia Therapeutics so important for investors?

The liabilities of Kazia Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Kazia Therapeutics take to modify the liabilities?

To change its liabilities, Kazia Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Kazia Therapeutics pay?

Over the past 12 months, Kazia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kazia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Kazia Therapeutics?

The current dividend yield of Kazia Therapeutics is .

When does Kazia Therapeutics pay dividends?

Kazia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kazia Therapeutics?

Kazia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kazia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kazia Therapeutics located?

Kazia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kazia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kazia Therapeutics from 11/8/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Kazia Therapeutics pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Kazia Therapeutics in the year 2023?

In the year 2023, Kazia Therapeutics distributed 0 AUD as dividends.

In which currency does Kazia Therapeutics pay out the dividend?

The dividends of Kazia Therapeutics are distributed in AUD.